# GlobeImmune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/globeimmune

- Industry: Pharmaceuticals
- Headquarters: Louisville, US
- Website: www.globeimmune.com
- Total disclosed funding: $119M
- Latest round: Series E (Jan 19, 2010)
- Investors on record: 23

## About

GlobeImmune, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative immunotherapies for treating cancer and infectious diseases.Founded in 1995 and headquartered in Louisville, US, GlobeImmune, Inc. focuses on creating therapeutic vaccines that harness the immune system to combat diseases. The company has undergone strategic pivots in its operational focus over the years but has remained dedicated to immunotherapy. In July 2014, GlobeImmune raised USD 15 mn through an IPO, offering 1.5 million shares at USD 10 per share. The company has completed a total of 13 deals as an investment target.GlobeImmune develops and markets proprietary therapeutic vaccines aimed at enhancing the immune response against specific tumor antigens, particularly for oncology applications. Their products are targeted towards healthcare providers and cancer treatment centers across North America and Europe, addressing a growing demand for advanced cancer therapies.In the most recent fiscal year of 2015, GlobeImmune reported a revenue of USD 6,457,733 and an EBITDA of USD -2,579,570. Their revenue is primarily generated through partnerships with healthcare institutions and collaborative research efforts focused on clinical trials involving their therapeutic products.GlobeImmune intends to leverage its recent IPO funding to advance the development of new therapeutic vaccines and expand into new markets, including Europe and Asia by 2025. The funding raised in July 2014 will support these initiatives, enhancing their product pipeline and increasing market presence.

## Funding rounds

- Series E, Jan 19, 2010, $18M — Adams Street Partners, HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, Wexford Capital, Lilly Ventures, Allianz Capital Partners, China Investment and Development Company, Generali Holding Vienna, GC and H Investments, Richard King Mellon Foundation, Pac-Link, Yasuda Enterprise Development, Medica Venture Partners, O-Bank, TaiAn Technologies Corporation, BSI Group, Celgene, WRF Capital, Biogen Idec New Ventures, Mass General Brigham Ventures, Mellon Family Investment Company
- Series D, May 14, 2009, $13M — HealthCare Ventures
- Series C, Jul 9, 2007, $41M — Adams Street Partners, HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, Wexford Capital, Lilly Ventures, Allianz Capital Partners, China Investment and Development Company, GC and H Investments, Richard King Mellon Foundation, Pac-Link, Yasuda Enterprise Development, Medica Venture Partners, O-Bank, TaiAn Technologies Corporation, Celgene, WRF Capital, Biogen Idec New Ventures, Mass General Brigham Ventures, Mellon Family Investment Company
- Series B, Jan 10, 2006, $4.1M — China Investment and Development Company, Pac-Link, Yasuda Enterprise Development
- Series B, Sep 15, 2005, $10M — Adams Street Partners, HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, Lilly Ventures, GC and H Investments, Medica Venture Partners, Genentech, Inc., Biogen Idec New Ventures, Mass General Brigham Ventures
- Series B, Jun 3, 2005, $24M — HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners
- Series A, Jun 18, 2003, $8M — HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners

## Investors

- HealthCare Ventures — Series A, Series B, Series C, Series D, Series E
- Morgenthaler Ventures (https://capitalatlas.ai/funds/morgenthaler-ventures) — Series A, Series B, Series C, Series E
- Sequel Venture Partners (https://capitalatlas.ai/funds/sequel-venture-partners) — Series A, Series B, Series C, Series E
- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series B, Series C, Series E
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series B, Series C, Series E
- GC and H Investments — Series B, Series C, Series E
- Medica Venture Partners (https://capitalatlas.ai/funds/medica-venture-partners) — Series B, Series C, Series E
- Genentech, Inc. — Series B
- Biogen Idec New Ventures (https://capitalatlas.ai/funds/biogen-idec-new-ventures) — Series B, Series C, Series E
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series B, Series C, Series E
- China Investment and Development Company (https://capitalatlas.ai/funds/china-investment-and-development-company) — Series B, Series C, Series E
- Pac-Link (https://capitalatlas.ai/funds/pac-link) — Series B, Series C, Series E
- Yasuda Enterprise Development (https://capitalatlas.ai/funds/yasuda-enterprise-development) — Series B, Series C, Series E
- Wexford Capital — Series C, Series E
- Allianz Capital Partners — Series C, Series E
- Richard King Mellon Foundation — Series C, Series E
- O-Bank (https://capitalatlas.ai/funds/o-bank) — Series C, Series E
- TaiAn Technologies Corporation (https://capitalatlas.ai/funds/taian-technologies-corporation) — Series C, Series E
- Celgene — Series C, Series E
- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series C, Series E
- Mellon Family Investment Company — Series C, Series E
- Generali Holding Vienna — Series E
- BSI Group — Series E